Please ensure Javascript is enabled for purposes of website accessibility Andy Acker, CFA - Janus Henderson Investors
For institutional investors in Denmark

Andy Acker, CFA

Portfolio Manager
Andy Acker, CFA | Janus Henderson Investors

Andy Acker is a Portfolio Manager on the Health Care and Biotech Teams at Janus Henderson Investors. He is also the Health Care Sector Lead. Andy was an assistant portfolio manager from 2003 to 2007. He joined Janus in 1999 as a research analyst focused on companies in the biotechnology and pharmaceutical industries. Prior to this, he worked as a strategy consultant for the Boston Consulting Group and as a health care analyst for Morgan Stanley Venture Partners.

Andy received his bachelor of science degree in biochemical sciences from Harvard University, graduating magna cum laude and Phi Beta Kappa. He also earned an MBA with honours from Harvard Business School. Andy holds the Chartered Financial Analyst designation and has 28 years of financial industry experience.

Download hi-res headshot

Articles Written

Healthcare’s small- and mid-cap opportunities amid aging populations
Features & Outlooks

Healthcare’s small- and mid-cap opportunities amid aging populations

With populations in some of the largest economies quickly graying, innovative small- and mid-cap healthcare companies could deliver new growth opportunities for investors.

Biotech stocks gain momentum from lower rates, innovation, and M&A
Timely & Topical

Biotech stocks gain momentum from lower rates, innovation, and M&A

Several factors are coming together that could help push the biotech sector higher.

Healthcare stocks: Positioned for a smoother ride in 2024?
Timely & Topical

Healthcare stocks: Positioned for a smoother ride in 2024?

Andy Acker and Dan Lyons share their outlook, saying a rapid pace of innovation and attractive valuations could propel the sector higher.

Medical devices, tools, and insurers make the case for a rebound
Timely & Topical

Medical devices, tools, and insurers make the case for a rebound

These healthcare subsectors offer an attractive combination of long-term growth drivers at below-average valuations.

Four questions: Why invest in healthcare now?
Timely & Topical

Four questions: Why invest in healthcare now?

Hear how advances in drug development, patient outcomes, and other trends are impacting the investment outlook for healthcare.

I&I therapies hit new milestones for patients and investors
Timely & Topical

I&I therapies hit new milestones for patients and investors

The stocks of inflammation and immunology (I&I) focused companies have outperformed in 2023 and could continue to deliver in the years ahead.

Navigating biotech’s “haves” and “have-nots”
Timely & Topical

Navigating biotech’s “haves” and “have-nots”

Performance in the sector has split between companies with positive clinical data and those without.

Healthcare stocks ready for new growth
Timely & Topical

Healthcare stocks ready for new growth

Attractive valuations and innovation are adding to the sector’s long-term appeal.

Global Perspectives: Healthcare’s underappreciated opportunities
Features & Outlooks

Global Perspectives: Healthcare’s underappreciated opportunities

How innovation, secular tailwinds – even regulation – are driving growth in the sector.

Hiding in plain sight: The investment case for healthcare
Timely & Topical

Hiding in plain sight: The investment case for healthcare

Why attractive valuations and new growth opportunities make healthcare worthy of another look by investors.

Keeping perspective on AI’s role in biotech
Timely & Topical

Keeping perspective on AI’s role in biotech

While technology is an important aspect of drug discovery, the value of new medicines – and the firms developing them – comes down to the quality of clinical data.

What’s next for biotech’s M&A boom?
Timely & Topical

What’s next for biotech’s M&A boom?

A regulatory hurdle may delay some merger and acquisition activity in the sector – but is unlikely to stop dealmaking.